Cargando…

Expression of SOX11 and HER2 and their association with recurrent breast cancer

BACKGROUND: Recurrent breast cancer occurs as a result of divergent gene expression in response to therapeutic intervention. A recent report showed that SOX11, an embryogenic mammary transcription factor, is overexpressed in breast cancer. HER2 is also dysregulated in breast cancer stem cells; howev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fu-Wen, Ao, Xiang, Fu, Shao-Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797835/ https://www.ncbi.nlm.nih.gov/pubmed/35116753 http://dx.doi.org/10.21037/tcr.2019.01.27

Ejemplares similares

Multi-Omics Analysis of SOX4, SOX11, and SOX12 Expression and the Associated Pathways in Human Cancers
por: Seok, Jaekwon, et al.
Publicado: (2021)

AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer
por: Al-Zahrani, Khalid N., et al.
Publicado: (2021)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Correction to: AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer
por: Al-Zahrani, Khalid N., et al.
Publicado: (2021)

Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

The three SoxC proteins—Sox4, Sox11 and Sox12—exhibit overlapping expression patterns and molecular properties
por: Dy, Peter, et al.
Publicado: (2008)

Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients
por: Ha, June-Hyung, et al.
Publicado: (2014)

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
por: Hosonaga, Mari, et al.
Publicado: (2014)

Expression and Clinicopathological Significance of SOX11 in Small-Cell Lung Cancer
por: Xinli, Wang, et al.
Publicado: (2022)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer
por: Zhou, Danyang, et al.
Publicado: (2023)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Carcinoma-Associated Fibroblasts Promote Growth of Sox2-Expressing Breast Cancer Cells
por: Dittmer, Angela, et al.
Publicado: (2020)

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
por: Strasser-Weippl, Kathrin, et al.
Publicado: (2015)

HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression
por: Luoh, Shiuh-Wen, et al.
Publicado: (2013)

Analysis of Genomic Alterations Associated with Recurrence in Early Stage HER2-Positive Breast Cancer
por: Kim, Yong-Seok, et al.
Publicado: (2022)

Expression of stemness genes in primary breast cancer tissues: the role of SOX2 as a prognostic marker for detection of early recurrence
por: Finicelli, Mauro, et al.
Publicado: (2014)

OCT4, SOX2, and NANOG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2(+) breast cancer patients
por: Yang, Fan, et al.
Publicado: (2018)

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer
por: Sparano, Joseph A., et al.
Publicado: (2022)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Systematic Investigation of the Multifaceted Role of SOX11 in Cancer
por: Sun, Qingqing, et al.
Publicado: (2022)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

New Advances in Targeted Therapy of HER2-Negative Breast Cancer
por: An, Junsha, et al.
Publicado: (2022)

Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients
por: Huang, Tzu-Ting, et al.
Publicado: (2018)

Connection between SOX7 Expression and Breast Cancer Prognosis
por: Qin, Chun-xin, et al.
Publicado: (2020)

Sox17 Promoter Methylation in Plasma DNA Is Associated With Poor Survival and Can Be Used as a Prognostic Factor in Breast Cancer
por: Fu, Deyuan, et al.
Publicado: (2015)

Association of SOX11 Polymorphisms in distal 3′UTR with Susceptibility for Schizophrenia
por: Sun, Cheng‐Peng, et al.
Publicado: (2020)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

sox4 And sox11 Function during Xenopus laevis Eye Development
por: Cizelsky, Wiebke, et al.
Publicado: (2013)

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers
por: Burdelski, Christoph, et al.
Publicado: (2015)

Stability and prognostic value of Slug, Sox9 and Sox10 expression in breast cancers treated with neoadjuvant chemotherapy
por: Riemenschnitter, Cosima, et al.
Publicado: (2013)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer
por: Qin, Guo-qiang, et al.
Publicado: (2014)

Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells
por: Rojhannezhad, Mahdieh, et al.
Publicado: (2023)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

gjSOX9 Cloning, Expression, and Comparison with gjSOXs Family Members in Gekko japonicus
por: Huang, Xingze, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nd7a0uguv4ar816shiqbmfl8or